Sarepta will present seven posters at the 27th Annual Neuromuscular Study Group Scientific Meeting, including first results from the Phase 4 ENDURE study of delandistrogene moxeparvovec (ELEVIDYS) in Duchenne muscular dystrophy. The data will be presented on Sept. 25, 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
